Barbero-Becerra VJ, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 14
Paginas: 731-733
Archivo PDF: 69.64 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Brashier DB, Sharma S, Mathur AG, Khare P, Gupta S. Boceprevir: A new hope against hepatitis C virus. J Pharmacol Pharmacother 2012; 3: 213-5.

2. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int 2012; 109: 352-8.

3. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology 2010; 138: 1112-22.

4. Gažák R, Walterová D, Kren V. Silybin and Silymarin-New and Emerging Applications in Medicine. Curr Med Chem 2007; 14: 315-38.

5. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104.

6. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of Tcell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132: 1925-36.

7. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.

8. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology 2010; 51: 1912-21.

9. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56: 1019-24.

10. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. A randomized controlled trial. JAMA 2012; 308: 274-282.

11. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy R, Wahed AS, et al. Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. J Clin Pharmacol 2010; 50: 434-49.

12. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 2005; 12: 559-67.

13. Ding T, Tian S, Zhang Z, Gu D, Chen Y, Shi Y, Sun Z. Determination of active component in silymarin by RP-LC and LC/MS. J Pharm Biomed Anal 2001; 26: 155-61.

14. Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464.